The purpose of this study is to explore the influence of neoadjuvant chemotherapy in the long term quality of life with advanced gastric cancer patients.

Preoperative adjuvant chemotherapy combined with postoperative adjuvant therapy mode was included in the 2018 version of the National Comprehensive Cancer Network (NCCN) guideline as an optional treatment (category 2B) for prospective resectable advanced gastric cancer cases (≥cT2, any N).At home and abroad, the research on neoadjuvant chemotherapy for advanced gastric cancer mainly focuses on the safety and long-term survival, and there are few studies on the quality of life. This study, according to EORTC QLQ-C30 and QLQ-STO22 assessment scale, explores the long term effect of neoadjuvant chemotherapy on the quality of life in patients with advanced gastric cancer.

Inclusion Criteria:

• Patients age older than 18 years (including 18 years old);
• Diagnosis of adenocarcinoma of the stomach
• The clinic stage is ≥T2 and any N stage
• Patient had curative surgical resection, including proximal, distal, or total gastrectomy

Exclusion Criteria:

• Psychiatric or psychological abnormality precluding informed consent or ability to complete questionnaires
• Non-psychiatric disorder causing a lack of capacity to give consent or an inability to complete questionnaires (ie dementia, stroke)
• Early gastric cancer.

Patients who have had curative resection at Beijing Cancer Hospital for advanced gastric cancer and finish the questionnaire.